Literature DB >> 21499930

Quality of life among testicular cancer survivors: a case-control study in the United States.

Christopher Kim1, Katherine A McGlynn, Ruth McCorkle, Ralph L Erickson, David W Niebuhr, Shuangge Ma, Barry Graubard, Briseis Aschebrook-Kilfoy, Kathryn Hughes Barry, Yawei Zhang.   

Abstract

INTRODUCTION: Evidence from previous studies has suggested there may be physical and mental changes in health among testicular cancer survivors. No studies have been conducted in the United States, however.
METHODS: Study participants were initially enrolled in the US Servicemen's Testicular Tumor Environmental and Endocrine Determinants (STEED) study between 2002 and 2005. A total of 246 TGCT (testicular germ cell tumor) cases and 236 non-testicular cancer controls participated in the current study, and completed a self-administered questionnaire. Mean time since diagnosis for cases was 14 years, and no less than five for all cases. Component scores determined from responses to questions about physical and mental health on SF36 were tabulated to yield two summary measures, physical component scores (PCS), and mental component scores (MCS). Component and summary scores were normalized to a score of 50 with a standard deviation of 10 by a linear T-score transformation.
RESULTS: Overall, cases may not suffer greatly in different quality of life than controls. When all cases and controls are compared, TGCT cases had lower PCS (mean: 51.9 95% CI: 50.6-53.2, P value: 0.037) than controls (mean: 53.6 95% CI: 52.7-54.6). MCS were not significantly different (P value: 0.091). In multivariate analyses, several physical health components were worse for TGCT cases such as role-physical (OR 1.19, 95% CI: 1.01-1.39) and general health (OR 1.26, 95% CI: 1.07-1.49) compared to controls. However, TGCT cases treated with chemotherapy had lower PCS (cases: 50.2, 95% CI: 47.6-52.8; controls: 53.6, 95% CI: 52.7-54.6, P value: 0.0032) and MCS (cases: 49.3, 95% CI: 46.5-52.1; controls: 52.0, 95% CI: 50.9-53.2, P value: 0.039). TGCT cases who received treatments other than chemotherapy did not differ from controls in either PCS or MCS. DISCUSSION: Physical and general health limitations may affect testicular cancer survivors. Men treated with chemotherapy, however, may be most likely to suffer adverse health outcomes due to a combination of body-wide effects on physical and mental factors which affect various aspects of physical health, mental health, and overall quality of life. And in particular, physical functioning, role-physical, and general health are strongly affected.

Entities:  

Mesh:

Year:  2011        PMID: 21499930      PMCID: PMC3149776          DOI: 10.1007/s11136-011-9907-6

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  31 in total

1.  The level of physical activity in long-term survivors of testicular cancer.

Authors:  L Thorsen; W Nystad; O Dahl; O Klepp; R M Bremnes; E Wist; S D Fosså
Journal:  Eur J Cancer       Date:  2003-06       Impact factor: 9.162

2.  Cumulative effects of cardiovascular disease risk factors on quality of life.

Authors:  B A Chambers; S S Guo; R Siervogel; G Hall; Wm C Chumlea
Journal:  J Nutr Health Aging       Date:  2002-05       Impact factor: 4.075

Review 3.  Late toxicity following curative treatment of testicular cancer.

Authors:  C Kollmannsberger; M Kuzcyk; F Mayer; J T Hartmann; L Kanz; C Bokemeyer
Journal:  Semin Surg Oncol       Date:  1999-12

4.  Fatigue, anxiety, and depression in long-term survivors of testicular cancer.

Authors:  Sophie D Fosså; Alv A Dahl; Jon H Loge
Journal:  J Clin Oncol       Date:  2003-04-01       Impact factor: 44.544

5.  Quality of life in long-term survivors of testicular cancer: a population-based case-control study.

Authors:  F Joly; J F Héron; L Kalusinski; P Bottet; D Brune; N Allouache; J Macé-Lesec'h; J E Couëtte; J Pény; M Henry-Amar
Journal:  J Clin Oncol       Date:  2002-01-01       Impact factor: 44.544

6.  Posttraumatic stress disorder and self-reported physical health status among U.S. Military personnel serving during the Gulf War period: a population-based study.

Authors:  Drue H Barrett; Caroline Carney Doebbeling; David A Schwartz; Margaret D Voelker; Kenneth H Falter; Robert F Woolson; Bradley N Doebbeling
Journal:  Psychosomatics       Date:  2002 May-Jun       Impact factor: 2.386

7.  Trends in the incidence of testicular germ cell tumors in the United States.

Authors:  Katherine A McGlynn; Susan S Devesa; Alice J Sigurdson; Linda M Brown; Lilian Tsao; Robert E Tarone
Journal:  Cancer       Date:  2003-01-01       Impact factor: 6.860

8.  Cardiovascular disease as a long-term complication of treatment for testicular cancer.

Authors:  R A Huddart; A Norman; M Shahidi; A Horwich; D Coward; J Nicholls; D P Dearnaley
Journal:  J Clin Oncol       Date:  2003-04-15       Impact factor: 44.544

9.  Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer.

Authors:  Alexandra W van den Belt-Dusebout; Ronald de Wit; Jourik A Gietema; Simon Horenblas; Marieke W J Louwman; Jacques G Ribot; Harald J Hoekstra; Gabey M Ouwens; Berthe M P Aleman; Flora E van Leeuwen
Journal:  J Clin Oncol       Date:  2007-10-01       Impact factor: 44.544

10.  Quality of life in good prognosis patients with metastatic germ cell cancer: a prospective study of the European Organization for Research and Treatment of Cancer Genitourinary Group/Medical Research Council Testicular Cancer Study Group (30941/TE20).

Authors:  Sophie D Fosså; Ronald de Wit; J Trevor Roberts; Peter M Wilkinson; Pieter H M de Mulder; Graham M Mead; Pat Cook; Linda de Prijck; Sally Stenning; Neil K Aaronson; Andrew Bottomley; Laurence Collette
Journal:  J Clin Oncol       Date:  2003-03-15       Impact factor: 44.544

View more
  20 in total

1.  The prevalence, severity, and correlates of psychological distress and impaired health-related quality of life following treatment for testicular cancer: a survivorship study.

Authors:  Allan Ben Smith; Phyllis Butow; Ian Olver; Tim Luckett; Peter Grimison; Guy C Toner; Martin R Stockler; Elizabeth Hovey; John Stubbs; Sandra Turner; George Hruby; Howard Gurney; Mahmood Alam; Keith Cox; Madeleine T King
Journal:  J Cancer Surviv       Date:  2015-07-16       Impact factor: 4.442

2.  The Sound of Silence: A Proxy for Platinum Toxicity.

Authors:  Jan Oldenburg; Jourik A Gietema
Journal:  J Clin Oncol       Date:  2016-07-05       Impact factor: 44.544

3.  Multi-Institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-Based Chemotherapy.

Authors:  Chunkit Fung; Howard D Sesso; Annalynn M Williams; Sarah L Kerns; Patrick Monahan; Mohammad Abu Zaid; Darren R Feldman; Robert J Hamilton; David J Vaughn; Clair J Beard; Christian K Kollmannsberger; Ryan Cook; Sandra Althouse; Shirin Ardeshir-Rouhani-Fard; Steve E Lipshultz; Lawrence H Einhorn; Sophie D Fossa; Lois B Travis
Journal:  J Clin Oncol       Date:  2017-02-27       Impact factor: 44.544

4.  Second to fourth digit ratio, handedness and testicular germ cell tumors.

Authors:  Britton Trabert; Barry I Graubard; Ralph L Erickson; Yawei Zhang; Katherine A McGlynn
Journal:  Early Hum Dev       Date:  2013-04-24       Impact factor: 2.079

5.  Health-related quality of life, depression, and sexual function in testicular cancer survivors in a developing country: a Serbian experience.

Authors:  Uros Bumbasirevic; Nebojsa Bojanic; Tatjana Pekmezovic; Aleksandar Janjic; Aleksandar Janicic; Bogomir Milojevic; Cane Tulic
Journal:  Support Care Cancer       Date:  2012-08-30       Impact factor: 3.603

Review 6.  [Carcinoma in situ of the testis: predisposition, evolution and early detection].

Authors:  K Biermann
Journal:  Pathologe       Date:  2011-11       Impact factor: 1.011

7.  Exploring the spectrum of late effects following radical orchidectomy for stage I testicular seminoma: a systematic review of the literature.

Authors:  Jennifer A Soon; Angelyn Anton; Javier Torres; Ruth Lawrence; Phillip Parente; Joseph McKendrick; Ian D Davis; Carmel Pezaro
Journal:  Support Care Cancer       Date:  2018-10-22       Impact factor: 3.603

8.  Health-related quality of life in young men with testicular cancer: validation of the Cancer Assessment for Young Adults (CAYA).

Authors:  Michael A Hoyt; Stefan J Cano; Christopher S Saigal; Annette L Stanton
Journal:  J Cancer Surviv       Date:  2013-08-06       Impact factor: 4.442

9.  Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional Study.

Authors:  Sarah L Kerns; Chunkit Fung; Patrick O Monahan; Shirin Ardeshir-Rouhani-Fard; Mohammad I Abu Zaid; AnnaLynn M Williams; Timothy E Stump; Howard D Sesso; Darren R Feldman; Robert J Hamilton; David J Vaughn; Clair Beard; Robert A Huddart; Jeri Kim; Christian Kollmannsberger; Deepak M Sahasrabudhe; Ryan Cook; Sophie D Fossa; Lawrence H Einhorn; Lois B Travis
Journal:  J Clin Oncol       Date:  2018-04-04       Impact factor: 44.544

Review 10.  Patient-Reported Outcomes Associated with Treatments for Testicular Cancer: A Systematic Review.

Authors:  Rebecca Mercieca-Bebber; Sayeda Kamrun Naher; Orlando Rincones; Allan Ben Smith; Martin R Stockler
Journal:  Patient Relat Outcome Meas       Date:  2021-06-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.